GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2006

Eli Lilly Amends Acquisition Price for ICOS to $2.3B

  • Eli Lilly and Company reached an agreement with ICOS to amend the merger agreement relating to the proposed acquisition of ICOS by Lilly. Under the revised terms, Lilly will acquire all of the outstanding shares of ICOS common stock at a price of $34 per share, for a total purchase price of approximately $2.3 billion.

    he proposed $34 price reflects a $2 per share increase from the $32 per share of the original merger agreement, and Lilly is affirming that this is its best and final offer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?